Page last updated: 2024-12-08

dronedarone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dronedarone: A non-iodinated derivative of amiodarone that is used for the treatment of ARRHYTHMIA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dronedarone : A member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID208898
CHEMBL ID184412
CHEBI ID50659
SCHEMBL ID110363
MeSH IDM0304036

Synonyms (72)

Synonym
AC-5012
bdbm50151864
HY-A0016
D02537
dronedarone (inn)
141626-36-0
dronedarone [inn]
methanesulfonamide, n-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-
sr 33589
n-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide
dronedarone
CHEBI:50659 ,
n-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide
n-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide
sr 33589b
multaq
L001445
AKOS005145680
sr33589
CHEMBL184412 ,
sr-33589
FT-0651916
n-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide
A807786
n-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]benzofuran-5-yl]methanesulfonamide;dronedarone
NCGC00188863-01
unii-jqz1l091y2
hsdb 7928
dronedarone [inn:ban]
jqz1l091y2 ,
methanesulfonamide, n-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]-
cas-141626-36-0
tox21_113008
dtxcid6028579
dtxsid3048653 ,
n-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl) methanesulfonamide
ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
CS-0384
S5787
dronedarone [vandf]
dronedarone [mi]
dronedarone [ema epar]
DB04855
dronedarone [mart.]
dronedarone [who-dd]
n-(2-butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl)methanesulfonamide
SCHEMBL110363
tox21_113008_1
NCGC00188863-02
gtpl7465
AB01566893_01
STL451011
n-[2-butyl-3-({4-[3-(dibutylamino)propoxy]phenyl}carbonyl)-1-benzofuran-5-yl]methanesulfonamide
J-520428
n-(2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl)methanesulfonamide
NCGC00188863-10
multaq; sr-33589; sr33589; sr 33589; sr-33589b
BCP21326
Q408637
n-[2-butyl-3-(p-{3-(dibutylamino)propoxy} benzoyl)-5-benzofuranyl]methanesulfonamide
n-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)methanesulfonamide
dronedarone base
mfcd00910331
HMS3749G19
AS-80328
EN300-304885
EX-A7762
n,n-dibutyl-3-
dronedarone (mart.)
dronedaronum
n-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-1-benzofuran-5-yl)methanesulfonamide
dronedarona

Research Excerpts

Overview

Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function. It is prudent to exercise caution when concurrently administering CYP2D6-metabolized β-blockers because of a lack of published data on potential drug interactions.

ExcerptReferenceRelevance
"Dronedarone is an antiarrhythmic drug proven to efficiently maintain sinus rhythm."( Effect of DrOnedarone on atrial fibrosis progression and atrial fibrillation recurrence postablation: Design of the EDORA randomized clinical trial.
Akoum, N; Bhatnagar, A; Dagher, L; El Hajjar, AH; Hua, H; Mansour, M; Marrouche, NF; Wazni, O, 2021
)
1.75
"Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function."( Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.
Calkins, H; Hohnloser, SH; Lip, GYH; Ludwigs, U; Nam, GB; Oldgren, J; Stewart, J; Ueng, KC; Vamos, M; Wieloch, M; Zhu, J, 2022
)
3.61
"Dronedarone is a moderate inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme and P-glycoprotein (P-gp)."( Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
He, QF; Jiao, Z; Wen, HN; Xiang, XQ; Yu, JG, 2022
)
1.64
"Dronedarone HCl (DRN) is an anti-arrhythmic drug indicated for atrial fibrillation. "( Dronedarone HCl-Quercetin Co-Amorphous System: Characterization and RP-HPLC Method Development for Simultaneous Estimation.
Bhat, K; Dengale, SJ; Mutalik, S; Navya Sree, KS, 2021
)
3.51
"Dronedarone is a CYP2D6 inhibitor; therefore, it is prudent to exercise caution when concurrently administering CYP2D6-metabolized β-blockers because of a lack of published data on potential drug interactions. "( Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Baek, IH; Kim, MS, 2018
)
2.33
"Dronedarone is an antiarrhythmic agent that was recently approved for the treatment of atrial fibrillation."( Dronedarone produces early regression of myocardial remodelling in structural heart disease.
Delgado-Baeza, E; Delgado-Martos, MJ; Desco, M; Gomez de Diego, JJ; Muñoz-Valverde, D; Quintana-Villamandos, B; Soto-Montenegro, ML, 2017
)
2.62
"Dronedarone is a new antiarrhythmic drug for the treatment of atrial fibrillation. "( Preparation, characterization and in vitro cytotoxicity study of dronedarone hydrochloride inclusion complexes.
Bender, CR; Fernandes, JR; Frizzo, CP; Macedo, LB; Marcolino, AIP; Mitjans, M; Nogueira-Librelotto, DR; Rolim, CMB; Vinardell, MP; Wust, KM, 2019
)
2.19
"Dronedarone is a multichannel-blocking antiarrhythmic drug for the treatment of atrial fibrillation. "( Cardioprotective Effects of Dronedarone Mediated by the Influence on the Expression of Urokinase-Type Plasminogen Activator Receptor.
Akin, I; Becher, T; Borggrefe, M; Kälsch, T; Kuschyk, J; Liebe, V; Michels, J; Röger, S; Rudic, B; Seiler, L; Stach, K; Trinkmann, F; Tülümen, E; Weiss, C, 2019
)
2.25
"Dronedarone is a new multichannel-blocking antiarrhythmic for the treatment of patients with atrial fibrillation. "( The protective effect of dronedarone on the structure and mechanical properties of the aorta in hypertensive rats by decreasing the concentration of symmetric dimethylarginine (SDMA).
Böger, RH; Delgado-Baeza, E; Delgado-Martos, MJ; González, MDC; Gutiérrez-Arzapalo, PY; Lüneburg, N; Muñoz, D; Quintana-Villamandos, B, 2019
)
2.26
"Dronedarone is a novel class III antiarrhythmic drug with moderate efficacy in preventing atrial arrhythmias. "( Usefulness of dronedarone in patients with atrial arrhythmias.
Bollmann, A; Hindricks, G; Husser, D; John, S; Kornej, J; Löbe, S; Salmáš, J, 2013
)
2.19
"Dronedarone is a new antiarrhythmic drug used in the treatment of atrial fibrillation (AF). "( Efficacy and tolerability of dronedarone for patients with atrial fibrillation.
Goldberger, JJ; Teme, T, 2013
)
2.12
"Dronedarone is a non-iodinated benzofuran derivative with antiarrhythmic properties. "( An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation.
Connolly, SJ; Halperin, JL; Hohnloser, SH; John Camm, A; Radzik, D, 2014
)
2.09
"Dronedarone is a benzofuran derivative of amiodarone newly approved in 2009 for the treatment of AF."( Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation.
Kim, J; Lee, EJ, 2014
)
1.48
"Dronedarone is an amiodarone analog that differs structurally from amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added. "( The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS.
Kowey, PR; Naccarelli, GV, 2014
)
2.22
"Dronedarone is an amiodarone-like antiarrhythmic drug associated with severe liver injury. "( Hepatic toxicity of dronedarone in mice: role of mitochondrial β-oxidation.
Bouitbir, J; Donzelli, M; Felser, A; Krähenbühl, S; Morand, R; Schnell, D; Stoller, A; Terracciano, L, 2014
)
2.17
"Dronedarone is a novel class III antiarrhythmic drug that is widely used in atrial fibrillation. "( Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224.
Katus, HA; Koepple, C; Scherer, D; Scholz, EP; Seyler, C; Thomas, D; Xynogalos, P; Zitron, E, 2014
)
2.13
"Dronedarone is a recent antiarrhythmic drug that has been developed for treatment of AF, with electrophysiological properties similar to amiodarone but with a lower incidence of side effects."( Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.
Bianco, D; Bizzarri, N; Brunelli, C; Ferrero, S; Parodi, A; Rosa, GM; Valbusa, A; Zawaideh, C, 2014
)
1.38
"Dronedarone is an interesting antiarrhythmic agent in well-selected groups of patients. "( Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.
Bianco, D; Bizzarri, N; Brunelli, C; Ferrero, S; Parodi, A; Rosa, GM; Valbusa, A; Zawaideh, C, 2014
)
2.1
"Dronedarone is a benzofuran derivative with a pharmacological profile similar to amiodarone but has a more rapid onset of action and a much shorter half-life (13-19 h). "( A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers.
Boddy, A; DiMarco, JP; Ellenbogen, KA; Ezekowitz, MD; Geba, GP; Kaszala, K; Koren, A; P, GG, 2015
)
2.08
"Dronedarone is a promising, relatively new antiarrhythmic agent characterized by structural similarities to amiodarone but without amiodarone's severe organ toxicity. "( Torsade de pointes tachycardia in a patient on dronedarone therapy.
Bronder, E; Garbe, E; Haverkamp, W; Huemer, M; Klimpel, A; Sarganas, G, 2015
)
2.12
"Dronedarone is a strong P-glycoprotein inhibitor with a potential to increase bioavailability of dabigatran. "( Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice.
Juhlin, T; Mochalina, N; Platonov, PG; Svensson, PJ; Wieloch, M, 2015
)
2.19
"Dronedarone is an amiodarone-like antiarrhythmic with a modified structure. "( Diffuse alveolar damage in a patient receiving dronedarone.
Ahuja, N; Casto, A; Nguyen, DV; Stack, S, 2015
)
2.12
"Dronedarone is a class III antiarrhythmic that has been used for management of atrial fibrillation in humans, but limited information was found in dogs. "( Acute effects of intravenous dronedarone on electrocardiograms, hemodynamics and cardiac functions in anesthetized dogs.
Buranakarl, C; Hamlin, RL; Kijtawornrat, A; Limprasutr, V; Saengklub, N; Sawangkoon, S, 2016
)
2.17
"Dronedarone is a less potent antiarrhythmic agent with structural and pharmacological properties similar to amiodarone."( [AMIODARONE AND THE THYROID FUNCTION].
Franceschi, M; Granić, R; Jukić, T; Kusić, Z; Punda, M; Staniĉić, J,
)
0.85
"Dronedarone is an antiarrhythmic agent approved in 2009 for the treatment of atrial fibrillation. "( Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
Chai, CL; Chan, EC; Chia, YM; Hong, Y; Koh, SK; Kojodjojo, P; Venkatesan, G; Yeo, RH; Zhou, L, 2016
)
2.13
"Dronedarone is a multichannel blocking antiarrhythmic drug that has been used for management of atrial fibrillation in humans, but the data in veterinary medicine are inadequate. "( Short-term effects of oral dronedarone administration on cardiac function, blood pressure and electrocardiogram in conscious telemetry dogs.
Del Rio, C; Hamlin, RL; Kijtawornrat, A; Saengklub, N; Sawangkoon, S; Youngblood, B, 2016
)
2.17
"As dronedarone is a potent mechanism-based inactivator of CYP3A4 and CYP3A5, a question arose if it exerts a similar inhibitory effect on CYP2J2, a prominent cardiac CYP450 enzyme."( Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.
Chai, CL; Chan, EC; Hong, Y; Karkhanis, A; Koh, SK; Kojodjojo, P; Lam, HY; Venkatesan, G; Zhou, L, 2016
)
1.19
"Dronedarone appears to be a useful drug in patients with paroxysmal or persistent atrial fibrillation."( Amiodarone and dronedarone: An update.
Hohnloser, SH; Vamos, M, 2016
)
1.51
"Dronedarone is a benzofuran derivative resembling amiodarone that was intended to reduce the iodine-associated tissue deposition and organ toxicity seen with the latter. "( The use of dronedarone for recurrent ventricular tachycardia: a case report and review of the literature.
Brent Mitchell, L; Kuriachan, V; Rizkallah, J, 2016
)
2.27
"Dronedarone is a novel antiarrhythmic drug with electrophysiological properties that are similar to those of amiodarone, but it does not contain iodine and thus does not cause iodine-related adverse reactions. "( Increased mortality after dronedarone therapy for severe heart failure.
Amlie, J; Carlsen, J; Crijns, H; Gøtzsche, O; Køber, L; Lévy, S; McMurray, JJ; Torp-Pedersen, C, 2008
)
2.09
"Dronedarone. Dronedarone is a benzofuran derivative pharmacologically related to amiodarone but without the iodine moiety. "( Dronedarone: a new treatment for atrial fibrillation.
Kowey, PR; Laughlin, JC, 2008
)
3.23
"Dronedarone appears to be an alternative but less-effective anti-arrhythmic agent and it does not have adverse effects on thyroid function."( Benzofuran derivatives and the thyroid.
Han, TS; Vanderpump, MP; Williams, GR, 2009
)
1.07
"Dronedarone is a new multichannel blocker for atrial fibrillation (AF) previously demonstrated to have both rhythm and rate control properties in paroxysmal and persistent AF. "( Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
Alings, A; Davy, JM; Herold, M; Hoglund, C; Radzik, D; Timmermans, A; Van Kempen, L, 2008
)
3.23
"Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation."( Effect of dronedarone on cardiovascular events in atrial fibrillation.
Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009
)
2.2
"Dronedarone is an amiodarone analogue without iodine moiety in its structure, and is similar to amiodarone with regard to its structural and electrophysiological properties. "( Dronedarone: a promising alternative for the management of atrial fibrillation.
Tandogan, I; Turgut, OO; Yalta, K; Yilmaz, A; Yilmaz, MB, 2009
)
3.24
"Oral dronedarone is a non-iodinated benzofurane derivative structurally related to amiodarone. "( Dronedarone.
Hoy, SM; Keam, SJ, 2009
)
2.31
"Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been developed for the treatment of atrial fibrillation and atrial flutter."( Dronedarone.
Kowey, PR; Patel, C; Yan, GX, 2009
)
2.52
"Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, with two molecular changes, and with a better side effect profile."( Dronedarone for atrial fibrillation: a new therapeutic agent.
Arora, BL; Arora, RR; Bhuriya, R; Patel, DD; Patel, PD; Singh, PP, 2009
)
2.52
"Dronedarone is a noniodinated amiodarone congener developed to maintain sinus rhythm. "( Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
Califf, RM; Hasselblad, V; Kong, DF; Peterson, ED; Piccini, JP; Washam, JB, 2009
)
2.1
"Dronedarone is a derivative of amiodarone that is free of iodine and less lipophilic. "( Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation.
Duray, GZ; Ehrlich, JR; Hohnloser, SH, 2010
)
3.25
"Dronedarone is a benzofuran derivative; specifically N-[2-Butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]methane-sulfonamide and its production process has been patented."( Dronedarone--a new alternative for management of atrial fibrillation.
Garg, RK; Hundal, M, 2010
)
2.52
"Dronedarone is a derivative of amiodarone indicated for the treatment of AF."( Dronedarone: current evidence and future questions.
Gleason, PP; Kjesbo, NK; Schafer, JA, 2010
)
2.52
"Dronedarone is an oral Class III antiarrhythmic agent which was recently approved by the US Food and Drug Administration for use in nonpermanent atrial fibrillation. "( Dronedarone: a safety comparison to amiodarone.
Clem, JR; Farver, DK; Fischer, JR; Johnson, TJ, 2010
)
3.25
"Dronedarone is a benzofuran derivative structurally similar to amiodarone but non-iodinated. "( [Clinical pharmacology and electrophysiological properties of dronedarone].
Goette, A; Hohnloser, S; Kirch, W; Lewalter, T; Pittrow, D, 2010
)
2.04
"Dronedarone is a new antiarrhythmic agent that was recently approved for the prevention of cardiovascular hospitalization driven by atrial fibrillation/flutter. "( Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?
Cingolani, E; Diamond, GA; Kaul, S; Singh, D, 2010
)
3.25
"Dronedarone is a new multichannel blocking antiarrhythmic drug for treatment of atrial fibrillation (AF). "( Dronedarone in patients with congestive heart failure: insights from ATHENA.
Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2010
)
3.25
"Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation. "( Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
Duray, GZ; Hohnloser, SH; Schmitt, J, 2010
)
3.25
"Dronedarone is a substrate for P-glycoprotein (P-gp) and will lead to an increase in concentration of P-gp substrates such as digoxin."( Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation.
Dorian, P, 2010
)
1.39
"Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been recently approved by the Food and Drug Administration to reduce cardiovascular hospitalization in patients with AF or atrial flutter."( Dronedarone: a review of characteristics and clinical data.
Baroletti, S; Catella, J; Cheng, JW; Ehle, M, 2010
)
2.52
"Dronedarone is a multichannel blocker with similar electrophysiological properties to amiodarone. "( Suppression of ventricular tachycardia with dronedarone: a case report.
Freudenberger, R; Levin, V; Marchlinski, FE; Shaaraoui, M, 2011
)
2.07
"Dronedarone is a newly approved antiarrhythmic agent with multichannel blocking properties similar to amiodarone. "( Worsening heart failure in the setting of dronedarone initiation.
Coons, JC; Plauger, KM; Seybert, AL; Sokos, GG, 2010
)
2.07
"Dronedarone is a novel multichannel blocker with antiadrenergic and vasodilatory properties. "( Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure.
Ghali, JK; Giles, T; Levine, TB; Radzik, D, 2010
)
2.21
"Dronedarone is an amiodarone analog with multichannel blocking electrophysiologic properties similar to those of amiodarone, but several structural differences."( Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.
Banchs, J; Gonzalez, M; Naccarelli, G; Penny-Peterson, E; Samii, S; Wolbrette, D, 2010
)
2.52
"Dronedarone is an antiarrhythmic agent recently approved by the United States Food and Drug Administration for the reduction of cardiovascular-related hospitalizations in patients with paroxysmal or persistent atrial fibrillation or atrial flutter. "( Dronedarone: a new antiarrhythmic agent.
Hofmann, PO; Oyetayo, OO; Rogers, CE, 2010
)
3.25
"Dronedarone is a new antiarrhythmic drug that may offer advantages for rhythm control, given its relative safety (although not in patients with decompensated heart failure), efficacy and tolerability."( Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study.
Lip, GY; Pamukcu, B, 2010
)
2.52
"Dronedarone is a multichannel blocker with electrophysiologic effects similar to amiodarone. "( A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
Banchs, JE; Gonzalez, MD; Naccarelli, GV; Penny-Peterson, E; Samii, S; Wolbrette, DL, 2010
)
2.05
"Dronedarone is a new antiarrhythmic agent, approved in January 2010 for the therapy of atrial fibrillation and for rate control in tachyarrhythmic atrial fibrillation. "( [Dronedarone].
Gonska, BD, 2010
)
2.71
"Dronedarone is a new anti-arrhythmic drug that has been developed to provide rhythm and rate control in AF patients with fewer side effects compared with amiodarone."( Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation.
Becker, R; Katus, HA; Schweizer, PA; Thomas, D, 2011
)
2.53
"Dronedarone is a multi-channel-blocking drug for the treatment of patients with atrial fibrillation (AF) or atrial flutter (AFL) with rate- and rhythm-controlling properties. "( Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2011
)
2.08
"Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been recently approved by Swissmedic for management of patients with atrial fibrillation or atrial flutter."( Dronedarone for the management of atrial fibrillation.
Brenner, R; Delacrétaz, E, 2011
)
2.53
"Dronedarone is an amiodarone-like benzofuran which lacks the iodine moiety and presents a methane sulfonyl group that decreases its lipophilicity, thus shortening the half-life and decreasing tissue accumulation."( Dronedarone.
Caballero, R; Delpón, E; López-Farré, A; Tamargo, J, 2011
)
2.53
"Dronedarone is a relatively new antiarrhythmic drug approved for paroxysmal or persistent atrial fibrillation. "( Dronedarone-induced digoxin toxicity: new drug, new interactions.
Chandra, PA; Frankel, R; Pednekar, M; Shani, J; Vallakati, A,
)
3.02
"Dronedarone is a first-line drug to prevent the recurrence of atrial fibrillation according to ESC guidelines. "( Reduction of myocardial infarct size by dronedarone in pigs--a pleiotropic action?
Heusch, G; Skyschally, A, 2011
)
2.08
"Dronedarone is a new benzofuran derivative that has been developed as an antiarrhythmic agent on the basis of the amiodarone molecular structure with the intent of maintaining the same pharmacological effects while reducing thyroid and pulmonary toxicity. "( Dronedarone for atrial fibrillation therapy.
Lombardi, F; Marzocchi, M, 2011
)
3.25
"Dronedarone is a derivative of amiodarone--a popular antiarrhythmic drug. "( Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Chen, X; Dai, X; Xie, C; Yang, S; Zhong, D, 2011
)
2.1
"Dronedarone is an antiarrhythmic drug with multichannel-blocking properties."( Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials.
Anastasiou-Nana, M; Dagres, N; Iliodromitis, EK; Lekakis, JP; Rallidis, LS; Varounis, C, 2011
)
2.53
"Dronedarone is a new drug recently approved for the treatment of arrhythmias, such as atrial fibrillation and/or atrial flutter."( Managing atrial fibrillation in the elderly: critical appraisal of dronedarone.
Fischer, GW; Trigo, P, 2012
)
1.34
"Dronedarone is an amiodarone derivative in which the 2,5-diiodophenyl moiety of the parental drug has been replaced with an unsubstituted phenyl group aiming to eliminate the thyroid toxicity frequently observed with amiodarone treatment."( In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile.
Benaim, G; Garcia-Marchan, Y; Hernandez-Rodriguez, V; Mujica-Gonzalez, S; Paniz-Mondolfi, A; Parra-Gimenez, N; Plaza-Rojas, L; Silva, ML; Uzcanga, G, 2012
)
1.36
"Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone and a better side effect profile."( Dronedarone-current status in management of atrial fibrillation.
Manakshe, G; Rao, BH,
)
2.3
"Dronedarone is a benzofuran derivative approved by the Food and Drug Administration to decrease the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) and associated cardiovascular risk factors who are in sinus rhythm or will undergo cardioversion. "( Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure.
Aikat, S; Chatterjee, S; Ghosh, J; Lichstein, E; Mukherjee, D, 2012
)
2.08
"Dronedarone is a therapy for the treatment of patients with paroxysmal and persistent atrial fibrillation or atrial flutter. "( Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.
Åkerborg, Ö; Bascle, S; Lindgren, P; Nilsson, J; Reynolds, M, 2012
)
2.14
"Dronedarone is a new antiarrhythmic agent that has only recently been approved for the therapy of atrial fibrillation (AF). "( Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study).
Boenigk, H; Braun-Dullaeus, RC; Esperer, HD; Genz, C; Herold, J; Kluba, K; Said, SM; Schmeisser, A; Wiedemann, AK, 2013
)
2.12
"Dronedarone is a new antiarrhythmic drug for patients with nonpermanent atrial fibrillation (AF). "( Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine.
Duncker, D; Gardiwal, A; Klein, G; König, T; Lüsebrink, U; Oswald, H; Schreyer, H, 2013
)
2.06
"Dronedarone is a chemical derivative of amiodarone (though having a significantly different clinical profile) with effects on multiple ion channels that proved effective in reducing the rate of the combined endpoint of death from any cause and cardiovascular hospitalization in patients with non-permanent AF enrolled in the ATHENA study."( [New antiarrhythmic drugs for the treatment of atrial fibrillation].
Botto, GL; Campana, C; Mariconti, B; Pentimalli, F; Russo, G, 2012
)
1.1
"Dronedarone is a new antiarrhythmic drug with an amiodarone-like benzofuran structure. "( Mechanisms of hepatocellular toxicity associated with dronedarone--a comparison to amiodarone.
Blum, K; Bouitbir, J; Felser, A; Krähenbühl, S; Lindinger, PW, 2013
)
2.08
"Dronedarone is a new antiarrhythmic currently approved for use among patients with nonpermanent atrial fibrillation (AF) based on the positive results of the ATHENA trial. "( Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial.
Salam, AM, 2012
)
3.26
"Dronedarone is a noniodinated benzofuran derivative that has been synthesized to overcome the limiting iodine-associated adverse effects of the potent antiarrhythmic drug amiodarone. "( Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.
Karle, CA; Kathofer, S; Katus, HA; Kiehn, J; Kreye, VA; Schoels, W; Thomas, D; Wimmer, AB; Wu, K; Zhang, W; Zitron, E, 2003
)
2.1
"Dronedarone is an antagonist at alpha- and beta-adrenoceptors and unlike amiodarone, has little effect at thyroid receptors."( Dronedarone: an amiodarone analogue.
Doggrell, SA; Hancox, JC, 2004
)
2.49
"Dronedarone is a noniodinated benzofuran derivative that has been developed to overcome the limiting iodine-associated adverse effects of the commonly used antiarrhythmic drug, amiodarone. "( The novel antiarrhythmic drug dronedarone: comparison with amiodarone.
Karle, CA; Kathofer, S; Thomas, D, 2005
)
2.06
"Dronedarone is a novel antiarrhythmic medication to treat atrial fibrillation. "( Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
Dale, KM; White, CM, 2007
)
3.23
"Dronedarone is a new antiarrhythmic agent for the treatment of atrial fibrillation. "( Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
Dale, KM; White, CM, 2007
)
3.23
"Dronedarone is an investigational antiarrhythmic agent that is designed to have similar cardiac effects to amiodarone but with fewer adverse effects."( A review of the investigational antiarrhythmic agent dronedarone.
Rowles, J; Tafreshi, MJ, 2007
)
1.31
"Dronedarone is a new antiarrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effects."( Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Aliot, EM; Capucci, A; Connolly, SJ; Crijns, HJ; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D; Singh, BN, 2007
)
2.5
"Dronedarone is a recently developed iodine-free compound (Sanofi Recherche), structurally related to amiodarone."( Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study.
Celestino, D; Elizari, MV; Medei, E; Moro, S; Sicouri, S, 2007
)
1.36
"Dronedarone is a new antiarrhythmic compound currently being developed for treatment of AF."( Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atria
Connolly, SJ; Crijns, HJ; Hohnloser, SH; Page, RL; Seiz, W; Torp-Petersen, C, 2008
)
1.28
"Dronedarone (DR) is a new compound with a pharmacological profile similar to that of AM, but iodine free."( In vitro effects of acute amiodarone and dronedarone on epicardial, endocardial, and M cells of the canine ventricle.
Celestino, D; Elizari, MV; Ferreiro, M; Medei, E; Moro, S; Sicouri, S, 2007
)
1.33

Effects

Dronedarone has a significant discontinuation rate due to both inefficacy and side effects in clinical practice. It has an atrial-selective property and has been used for management of AF in humans, but limited information is available in dogs.

Dronedarone has been shown to prevent atrial fibrillation/ flutter (AF/AFl) recurrences in several multi-center trials. The drug has been demonstrated to be harmful in patients with recent decompensated heart failure.

ExcerptReferenceRelevance
"Dronedarone has an atrial-selective property and has been used for management of AF in humans, but limited information is available in dogs."( Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation.
Hamlin, RL; Kijtawornrat, A; Limprasutr, V; Saengklub, N; Sawangkoon, S, 2017
)
2.62
"Dronedarone has a significant discontinuation rate due to both inefficacy and side effects in clinical practice. "( Efficacy and tolerability of dronedarone for patients with atrial fibrillation.
Goldberger, JJ; Teme, T, 2013
)
2.12
"Dronedarone has a multifaceted mechanism of action similar to that of amiodarone."( Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
Dale, KM; White, CM, 2007
)
2.5
"Dronedarone has a favourable benefit/risk ratio, with the absence of any proarrhythmic effects."( Dronedarone: drondarone, SR 33589, SR 33589B.
, 2007
)
2.5
"Dronedarone has an atrial-selective property and has been used for management of AF in humans, but limited information is available in dogs."( Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation.
Hamlin, RL; Kijtawornrat, A; Limprasutr, V; Saengklub, N; Sawangkoon, S, 2017
)
2.62
"Dronedarone has a significant discontinuation rate due to both inefficacy and side effects in clinical practice. "( Efficacy and tolerability of dronedarone for patients with atrial fibrillation.
Goldberger, JJ; Teme, T, 2013
)
2.12
"Dronedarone has been shown to prevent atrial fibrillation/ flutter (AF/AFl) recurrences in several multi-center trials."( The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS.
Kowey, PR; Naccarelli, GV, 2014
)
1.5
"Dronedarone has been demonstrated to be harmful in patients with recent decompensated heart failure. "( Dronedarone does not affect infarct volume as assessed by magnetic resonance imaging in a porcine model of myocardial infarction.
Bukowska, A; Evert, M; Goette, A; Kühn, JP; Lendeckel, U; Linke, J; Peters, B; Utpatel, K; Wolke, C, 2015
)
3.3
"Dronedarone has failed to make an impact on AAD prescribing."( The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014.
Ahsan, SY; Di Mario, C; Hayward, C; Lyon, AR; Patel, HC; Patel, K; Rowland, E, 2016
)
1.16
"Dronedarone has proved efficacious without toxic or proarrhythmic effects and has minimal side effects, but remaining concerns exist regarding its use in patients with advanced heart failure."( Dronedarone: a new treatment for atrial fibrillation.
Kowey, PR; Laughlin, JC, 2008
)
2.51
"Dronedarone has undergone thorough clinical evaluation in various patient populations."( Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation.
Duray, GZ; Ehrlich, JR; Hohnloser, SH, 2010
)
2.52
"Dronedarone has antiarrhythmic properties of all Vaughan-Williams classes."( [Clinical pharmacology and electrophysiological properties of dronedarone].
Goette, A; Hohnloser, S; Kirch, W; Lewalter, T; Pittrow, D, 2010
)
1.32
"Dronedarone has been developed for treatment of atrial fibrillation (AF) or atrial flutter (AFL). "( Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.
Christiansen, CB; Køber, L; Torp-Pedersen, C, 2010
)
2.21
"Dronedarone has been recently approved for clinical use by the Food and Drug Administration and by the European Medicines Agency."( Dronedarone: an emerging therapy for atrial fibrillation.
Rosei, EA; Salvetti, M, 2010
)
2.52
"Dronedarone has not been studied in humans as an agent to suppress ventricular arrhythmias."( Suppression of ventricular tachycardia with dronedarone: a case report.
Freudenberger, R; Levin, V; Marchlinski, FE; Shaaraoui, M, 2011
)
1.35
"Dronedarone has been viewed as a potential therapeutic alternative for amiodarone because of a lower risk for pulmonary, thyroid, and dermatologic adverse effects."( Dronedarone: an alternative to amiodarone?
Cohenour, FV; Freeman, MK; Hughes, PJ; Price, EM, 2010
)
2.52
"Dronedarone has been documented to prevent atrial fibrillation recurrences and also has efficacy in slowing the ventricular response during episodes of atrial fibrillation."( A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
Banchs, JE; Gonzalez, MD; Naccarelli, GV; Penny-Peterson, E; Samii, S; Wolbrette, DL, 2010
)
1.33
"Dronedarone has been shown to reduce cardiovascular hospitalizations or death in patients with atrial fibrillation (AF) and additional risk factors. "( Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies.
Connolly, SJ; Duray, GZ; Hohnloser, SH; Torp-Pedersen, C, 2011
)
2.2
"Dronedarone has also been shown to reduce ventricular rate and the incidence of hospitalization due to cardiovascular events."( The management of patients with atrial fibrillation and dronedarone's place in therapy.
Boiangiu, C; Cohen, M, 2011
)
1.34
"Dronedarone has been approved by the Food and Drug Administration (FDA), and its use as a safe antiarrhythmic has been extensively documented."( In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile.
Benaim, G; Garcia-Marchan, Y; Hernandez-Rodriguez, V; Mujica-Gonzalez, S; Paniz-Mondolfi, A; Parra-Gimenez, N; Plaza-Rojas, L; Silva, ML; Uzcanga, G, 2012
)
1.36
"Dronedarone has been associated with a reduced number of first hospitalisation due to acute coronary syndromes. "( Dronedarone reduces arterial thrombus formation.
Akhmedov, A; Beer, HJ; Breitenstein, A; Camici, GG; Duru, F; Luscher, TF; Riem, HH; Sluka, SH; Steffel, J; Stivala, S; Studt, JD; Tanner, FC, 2012
)
3.26
"Dronedarone has been evaluated in several large clinical trials, which have shown reduced mortality and hospitalization rates in patients with non-permanent AF."( Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.
Adlan, AM; Lip, GY, 2013
)
1.41
"dronedarone has greater, and KB-130015 has smaller, toxicity than amiodarone toward alveolar macrophages; and 3)."( Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship.
Baritussio, A; Bigler, L; Bruttomesso, D; Duner, E; Follath, F; Ha, HR; Pettenazzo, A; Quaglino, D; Realdi, G, 2004
)
1.04
"Dronedarone has since undergone further extensive evaluation in three pivotal phase III trials."( Dronedarone: an emerging agent with rhythm- and rate-controlling effects.
Ehrlich, JR; Hohnloser, SH; Wegener, FT, 2006
)
2.5
"Dronedarone has a multifaceted mechanism of action similar to that of amiodarone."( Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
Dale, KM; White, CM, 2007
)
2.5
"Dronedarone has a favourable benefit/risk ratio, with the absence of any proarrhythmic effects."( Dronedarone: drondarone, SR 33589, SR 33589B.
, 2007
)
2.5

Actions

Dronedarone may increase exposure and the risk of major bleeding when prescribed with a direct oral anticoagulant (DOAC) Dron Cedarone can inhibit P-glycoprotein-mediated digoxin clearance and increase steady-state digoxin level 2.5 times.

ExcerptReferenceRelevance
"Dronedarone may increase exposure and the risk of major bleeding when prescribed with a direct oral anticoagulant (DOAC). "( Risk of Major Bleeding in Patients With Atrial Fibrillation Taking Dronedarone in Combination With a Direct Acting Oral Anticoagulant (From a U.S. Claims Database).
Boiron, R; Gandhi, SK; Reiffel, JA; Wieloch, M, 2021
)
2.3
"Dronedarone may increase digoxin plasma levels through inhibition of P-glycoprotein. "( Evaluating the Risk of Digitalis Intoxication Associated With Concomitant Use of Dronedarone and Digoxin Using Real-World Data.
Boiron, R; Gandhi, S; Juhaeri, J; Kechemir, H; Lin, S; Wieloch, M; Wu, C, 2021
)
2.29
"Dronedarone promotes infarct healing via regulation of periostin and might contribute to the limitation of its expansion as well as cardiac rupture."( Integration of "omics" techniques: Dronedarone affects cardiac remodeling in the infarction border zone.
Bukowska, A; Chilukoti, RK; Darm, K; Goette, A; Homuth, G; Lendeckel, J; Lendeckel, U; Peters, B; Scharf, C; Sühling, M; Utpatel, K; Völker, U; Wolke, C, 2018
)
1.48
"Dronedarone will cause a small increase in creatinine concentrations, without a change in glomerular filtration rate (GFR)."( Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation.
Dorian, P, 2010
)
1.39
"Dronedarone can inhibit P-glycoprotein-mediated digoxin clearance and increase steady-state digoxin level 2.5 times."( Dronedarone-induced digoxin toxicity: new drug, new interactions.
Chandra, PA; Frankel, R; Pednekar, M; Shani, J; Vallakati, A,
)
2.3
"Dronedarone may increase mortality and heart failure hospitalization in patients with advanced NYHA class and in patients with permanent AF, preventing its use in these settings."( Drug safety evaluation of dronedarone in atrial fibrillation.
De Ferrari, GM; Dusi, V, 2012
)
1.4
"Dronedarone may increase the risk of mortality in patients with congestive heart failure."( Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
Dale, KM; White, CM, 2007
)
2.5
"Dronedarone may modestly inhibit INCX in a therapeutic concentration range."( Acute inhibitory effect of dronedarone, a noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes.
Kimura, J; Watanabe, Y, 2008
)
1.36

Treatment

Treatment with dronedarone 200mg/kg/day had no effect on body weight, serum transaminases and bilirubin, and hepatic mitochondrial function in both wild-type and jvs(+/-) mice.

ExcerptReferenceRelevance
"Dronedarone treatment significantly reduced the risk of first CV hospitalization (P < 0.0001 vs."( Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study.
Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C, 2011
)
1.49
"Treatment with dronedarone 200mg/kg/day had no effect on body weight, serum transaminases and bilirubin, and hepatic mitochondrial function in both wild-type and jvs(+/-) mice."( Hepatic toxicity of dronedarone in mice: role of mitochondrial β-oxidation.
Bouitbir, J; Donzelli, M; Felser, A; Krähenbühl, S; Morand, R; Schnell, D; Stoller, A; Terracciano, L, 2014
)
1.07
"Treatment with dronedarone caused prolongation of QT(c)."( Chronic amiodarone-induced inhibition of the Na+-K+ pump in rabbit cardiac myocytes is thyroid-dependent: comparison with dronedarone.
Bewick, NL; Buhagiar, KA; Delbridge, L; Fernandes, C; Hansen, PS; Hemsworth, PD; Pitt, AD; Rasmussen, HH; Whalley, DW, 2003
)
0.87

Toxicity

Dronedarone was designed to have similar electrophysiological properties with a less toxic profile. It was equally effective irrespective of whether class Ic or sotalol were stopped for lack of efficacy or adverse events (AEs)

ExcerptReferenceRelevance
" It is a noniodinized amiodarone analogue and believed to be without the adverse effects of amiodarone."( Efficacy and safety of dronedarone: a review of randomized trials.
Christiansen, CB; Køber, L; Torp-Pedersen, C, 2010
)
0.67
" Based upon the investigational clinical trials to date, it appears that dronedarone has an established efficacy when compared to placebo along with exhibiting a minimal adverse effect profile."( Dronedarone: a safety comparison to amiodarone.
Clem, JR; Farver, DK; Fischer, JR; Johnson, TJ, 2010
)
2.03
" Main safety endpoint (MSE) was occurrence of thyroid-, hepatic-, pulmonary-, neurologic-, skin-, eye-, or gastrointestinal-specific events, or premature study drug discontinuation following an adverse event."( A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Davy, JM; De Ferrari, GM; Le Heuzey, JY; Radzik, D; Santini, M; Zhu, J, 2010
)
0.58
" Amiodarone is a last resort, mainly because of its numerous adverse effects."( Dronedarone. atrial fibrillation: too many questions about long-term adverse effects.
, 2010
)
1.8
" Class Ic agents increase mortality in patients with structural heart disease, and amiodarone harbors an extensive side effect profile despite its efficacy in maintaining sinus rhythm."( Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation.
Becker, R; Katus, HA; Schweizer, PA; Thomas, D, 2011
)
1.81
" Amiodarone (Cordarone, and others) is more effective for this indication, but its use is often limited by its adverse effects, including thyroid and pulmonary toxicity."( Safety of dronedarone (Multaq).
, 2011
)
0.77
" Dronedarone has been approved by the Food and Drug Administration (FDA), and its use as a safe antiarrhythmic has been extensively documented."( In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile.
Benaim, G; Garcia-Marchan, Y; Hernandez-Rodriguez, V; Mujica-Gonzalez, S; Paniz-Mondolfi, A; Parra-Gimenez, N; Plaza-Rojas, L; Silva, ML; Uzcanga, G, 2012
)
1.55
"Spontaneous reports in the United States Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) database generated between July 1, 2009, and June 30, 2011."( Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting.
Hiatt, WR; Kao, DP; Krantz, MJ, 2012
)
0.68
"All reports of adverse events during the study period were reviewed to identify cardiac events associated with any approved drug in the United States."( Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting.
Hiatt, WR; Kao, DP; Krantz, MJ, 2012
)
0.68
" Adverse effects occurred in 31."( Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study).
Boenigk, H; Braun-Dullaeus, RC; Esperer, HD; Genz, C; Herold, J; Kluba, K; Said, SM; Schmeisser, A; Wiedemann, AK, 2013
)
0.68
" Of all the antiarrhythmic drugs hitherto used, AM has the most adverse effects on the thyroid gland."( [Effect of amiodarone on the thyroid function and safety of the therapy--what's new].
Czarnywojtek, A; Florek, E; Hen, K; Ruchała, M; Stangierski, A; Warmuz-Stangierska, I; Zdanowska, J, 2012
)
0.38
" Dronaderone is a novel antiarrhythmic that is similar in composition to amiodarone, but is non-iodinated and also has a methane-sulfonyl group, significantly decreasing its incidence of adverse effects as compared to amiodarone."( Dronaderone-induced phototoxicity.
Elpern, DJ; Ladizinski, B, 2013
)
0.39
"Dronedarone could represent an effective and safe option in patients previously treated with AADs, especially class Ic AADs and sotalol."( Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014
)
2.16
" Dronedarone was equally effective irrespective of whether class Ic or sotalol were stopped for lack of efficacy or adverse events (AEs)."( Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014
)
1.62
"8 % of all patients in the safety set) had at least one adverse drug reaction (ADR) causally related to dronedarone."( One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care.
Benninger, G; Bosch, RF; Goette, A; Paar, WD; Pittrow, D; von Stritzky, B, 2015
)
0.86
"In our experience, dronedarone has been at least as effective and safe as flecainide, despite it was most frequently prescribed in patients with worse baseline risk profile."( [Comparison of the efficacy and safety of dronedarone and flecainide as maintenance antiarrhythmic therapy for sinus rhythm in atrial fibrillation].
Chamorro Fernández, AJ; Chamorro Fernández, CI; Grau Jornet, G; Nuñez Villota, J; Ruiz Nodar, JM; Sánchez Soriano, RM,
)
0.72
"Dronedarone, a derivative of amiodarone with structural modifications, was designed to have similar electrophysiological properties with a less toxic profile."( Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation.
Aronow, WS; Khan, MH; Rochlani, Y, 2017
)
2.21
"Anti-atrial fibrillatory, proarrhythmic and cardiodepressive profiles of dronedarone were analyzed using the halothane-anesthetized beagle dogs (n = 4) to create a standard protocol for clarifying both efficacy and adverse effects of anti-atrial fibrillatory drugs."( In vivo Analysis of the Anti-atrial Fibrillatory, Proarrhythmic and Cardiodepressive Profiles of Dronedarone as a Guide for Safety Pharmacological Evaluation of Antiarrhythmic Drugs.
Ando, K; Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Lubna, NJ; Motokawa, Y; Naito, AT; Nakamura, Y; Sugiyama, A; Yamazaki, H, 2018
)
0.93
"Develop a flexible analytic tool for the Food and Drug Administration's (FDA's) Sentinel System to assess adherence to safe use recommendations with two capabilities: characterize adherence to patient monitoring recommendations for a drug, and characterize concomitant medication use before, during, and/or after drug therapy."( A new analytic tool developed to assess safe use recommendations.
Cocoros, NM; Ding, Y; Fazio-Eynullayeva, E; Haynes, K; Izem, R; Ju, J; Lee, JY; Major, JM; Nguyen, M; Petrone, AB; Wagner, A, 2019
)
0.51
"We developed a tool for use in databases formatted to the Sentinel Common Data Model that can assess adherence to safe use recommendations involving patient monitoring and concomitant drug use over time."( A new analytic tool developed to assess safe use recommendations.
Cocoros, NM; Ding, Y; Fazio-Eynullayeva, E; Haynes, K; Izem, R; Ju, J; Lee, JY; Major, JM; Nguyen, M; Petrone, AB; Wagner, A, 2019
)
0.51
" Rates of treatment-emergent adverse events were 83."( Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study.
Calkins, H; Corp Dit Genti, V; Hohnloser, SH; Koren, A; Kowey, PR; Torp-Pedersen, CT; Vamos, M; Wieloch, M, 2020
)
0.87
"This retrospective study included 1777 non-permanent AF patients taking rivaroxaban for ≥ 1 month between 2011 and 2016 from a multicenter cohort in Taiwan, and compared concomitant AAD use against clinical outcome endpoints for safety, effectiveness, and major adverse cardiac events (MACE)."( Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ, 2021
)
0.62
" The incidence of all treatment-emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation was comparable among males and females, and increased with increasing age."( Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter.
Bhattacharyya, N; Bogard, A; Curtis, AB; Hohnloser, SH; Malik, A; Stewart, J; Zeitler, EP, 2022
)
1.03
"The use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is complex because impaired renal clearance can cause increased drug levels, and risk of intolerance or adverse events."( Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.
Atar, D; Crijns, HJGM; Kowey, P; Ludwigs, U; Pak, HN; Reiffel, J; Stewart, J; Thind, M; Wieloch, M; Zareba, W; Zhu, J, 2022
)
1.03
" eGFR stratification had no significant effect on serious adverse events, deaths, or treatment discontinuations."( Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.
Atar, D; Crijns, HJGM; Kowey, P; Ludwigs, U; Pak, HN; Reiffel, J; Stewart, J; Thind, M; Wieloch, M; Zareba, W; Zhu, J, 2022
)
1.03

Pharmacokinetics

The objectives of the current study were to characterize the pharmacokinetic profile of dronedarone in the rat and to examine the effect of hyperlipidemia on its pharmacokinetics. The one-compartment model with first-order absorption and elimination was sufficient to explain the Pharmacokinetic characters after single oral administration of carvedilol.

ExcerptReferenceRelevance
" Pharmacokinetic parameters of metoprolol were investigated at day 5 and at day 13 in 44 subjects, 39 extensive metabolizers and five poor metabolizers for CYP2D6."( Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Caplain, H; Damy, T; Hulot, JS; Lechat, P; Pousset, F, 2004
)
0.56
" This overview summarizes the pharmacokinetic and pharmacodynamic properties of dronedarone, evaluates its potential application to daily clinical cardiology practice according to the evidence provided by clinical trials, and provides a future clinical perspective for the use of this drug."( Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice.
Lip, GY; Pamukcu, B, 2011
)
2.04
" Our findings demonstrate the successful application of the validated LC-MS/MS method to a pharmacokinetic study after a single oral administration of 400mg dronedarone to six healthy volunteers."( Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Chen, X; Dai, X; Xie, C; Yang, S; Zhong, D, 2011
)
0.86
" In this study, in vivo-based [I]/Ki values were used to predict the DDI risks of a P-gp substrate dabigatran etexilate (DABE) using physiologically based pharmacokinetic (PBPK) modelling."( Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Hu, ZY; Zhao, Y, 2014
)
0.4
"This approach accurately predicted the effects of five P-gp inhibitors on DABE pharmacokinetics (98-133% and 89-104% for the ratios of AUC and Cmax respectively)."( Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Hu, ZY; Zhao, Y, 2014
)
0.4
" In the present study, a dynamic physiologically based pharmacokinetic (PBPK) model was developed in Simcyp for clopidogrel and clopi-H4 using a specific sequential metabolite module in four populations with phenotypically different CYP2C19 activity (poor, intermediate, extensive, and ultrarapid metabolizers) receiving a loading dose of 300 mg followed by a maintenance dose of 75 mg."( Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
Boulenc, X; Djebli, N; Fabre, D; Fabre, G; Hurbin, F; Sultan, E, 2015
)
0.42
"The objectives of the current study were to characterize the pharmacokinetic profile of dronedarone in the rat, and to examine the effect of hyperlipidemia on its pharmacokinetics."( The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats.
Brocks, DR; Jardan, YA, 2016
)
0.96
" The one-compartment model with first-order absorption and elimination was sufficient to explain the pharmacokinetic characters after single oral administration of carvedilol to both vehicle-pretreated and dronedarone-pretreated rats."( Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Baek, IH; Kim, MS, 2018
)
1.07
" The developed dronedarone physiologically based pharmacokinetic (PBPK) model was verified using reported drug-drug interactions (DDIs) between dronedarone and CYP3A4 and P-gp substrates."( Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
He, QF; Jiao, Z; Wen, HN; Xiang, XQ; Yu, JG, 2022
)
1.27
" We aimed to develop, verify and validate a physiologically based pharmacokinetic (PBPK) model of dronedarone and its major metabolite, N-desbutyldronedarone (NDBD), to prospectively interrogate this clinically relevant DDI in healthy and mild renal impairment populations."( Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Ang, XJ; Chan, ECY; Leow, JWH, 2023
)
1.35

Compound-Compound Interactions

Major bleedings were rare among patients with atrial fibrillation treated with dronedarone in combination with apixaban or warfarin. The use of rivaroxaban with AADs appears to be well tolerated, warranting further investigation.

ExcerptReferenceRelevance
" An important drug-drug interaction between amiodarone and vitamin K antagonists is encountered frequently in daily clinical practice."( Dronedarone and vitamin K antagonists: a review of drug-drug interactions.
Becker, RC; Fiuzat, M; Shirolkar, SC, 2010
)
1.8
" The electrophysiologic mechanisms of ranolazine in combination with class III drugs were studied in an isolated whole-heart model of stretch-related AF."( Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T, 2013
)
0.39
"In vitro inhibitory potency (Ki )-based predictions of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) are hampered by the substantial variability in inhibitory potency."( Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Hu, ZY; Zhao, Y, 2014
)
0.4
"There have been concerns about bleeding risks for patients with atrial fibrillation treated with dronedarone in combination with new oral anticoagulants (NOACs)."( Safety of apixaban in combination with dronedarone in patients with atrial fibrillation.
Friberg, L, 2018
)
0.97
" All patients with atrial fibrillation who used dronedarone in combination with apixaban or warfarin during 2013-2016 were identified."( Safety of apixaban in combination with dronedarone in patients with atrial fibrillation.
Friberg, L, 2018
)
1.01
"Major bleedings were rare among patients with atrial fibrillation treated with dronedarone in combination with apixaban or warfarin."( Safety of apixaban in combination with dronedarone in patients with atrial fibrillation.
Friberg, L, 2018
)
0.98
"Concomitant use of rivaroxaban with AADs appears to be well tolerated, warranting further investigation into the apparent benefits of a reduced dose of rivaroxaban combined with dronedarone."( Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ, 2021
)
0.81
" The developed dronedarone physiologically based pharmacokinetic (PBPK) model was verified using reported drug-drug interactions (DDIs) between dronedarone and CYP3A4 and P-gp substrates."( Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
He, QF; Jiao, Z; Wen, HN; Xiang, XQ; Yu, JG, 2022
)
1.27
"Despite potential enzyme- and transporter-mediated drug-drug interactions (DDIs) between dronedarone and rivaroxaban in atrial fibrillation (AF) patients, pharmacokinetic/pharmacodynamic data remain limited to guide clinical practice."( Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Ang, XJ; Chan, ECY; Leow, JWH, 2023
)
1.36

Bioavailability

Dronedarone HCl (DRD), owing to its poor aqueous solubility and extensive presystemic metabolism shows low oral bioavailability of about 4% without food, which increases to approximately 15% when administered with a high fat meal. Addition of dron Cedarone (800-1600mg daily) to metoprolol (200 mg daily) increases bioavailability in CYP2D6 e.

ExcerptReferenceRelevance
" Addition of dronedarone (800-1600 mg daily) to metoprolol (200 mg daily) increases bioavailability of metoprolol in CYP2D6 extensive metabolizers and induces an additive dronedarone dose-dependent negative inotropic effect."( Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Caplain, H; Damy, T; Hulot, JS; Lechat, P; Pousset, F, 2004
)
0.93
" Compared with amiodarone, dronedarone has poor bioavailability and a shorter terminal disposition half-life, which dictates a twice-daily dosing regimen."( Dronedarone: an alternative to amiodarone?
Cohenour, FV; Freeman, MK; Hughes, PJ; Price, EM, 2010
)
2.1
"Dronedarone is a strong P-glycoprotein inhibitor with a potential to increase bioavailability of dabigatran."( Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice.
Juhlin, T; Mochalina, N; Platonov, PG; Svensson, PJ; Wieloch, M, 2015
)
2.19
" The drug showed poor bioavailability (<20%) after oral and intraperitoneal administration."( The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats.
Brocks, DR; Jardan, YA, 2016
)
0.74
"The objective of the present study was to develop a proliposomal formulation to increase the oral bioavailability of dronedarone hydrochloride (dronedarone HCl) by enhancing solubility, dissolution, and/or intestinal absorption."( Formulation of Dronedarone Hydrochloride-Loaded Proliposomes: In Vitro and In Vivo Evaluation Using Caco-2 and Rat Model.
Betageri, GV; Kovvasu, SP; Kunamaneni, P; Rueda, J; Yeung, S, 2019
)
1.08
"Dronedarone HCl (DRD), owing to its poor aqueous solubility and extensive presystemic metabolism shows low oral bioavailability of about 4% without food, which increases to approximately 15% when administered with a high fat meal."( Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
Gambhire, MS; Gambhire, VM; Ranpise, NS, 2019
)
2.25
"Solid lipid nanoparticles (SLN) were designed with glyceryl monstearate (GMS) in order to improve oral bioavailability of DRD."( Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
Gambhire, MS; Gambhire, VM; Ranpise, NS, 2019
)
0.81
"These results indicated that dronedarone HCl loaded SLN could potentially be exploited as a delivery system for improving oral bioavailability by minimizing first pass metabolism."( Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
Gambhire, MS; Gambhire, VM; Ranpise, NS, 2019
)
1.1
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Resting values of LVEF, FS, +LVdP/dt, and MBP remained unchanged whatever the drug and the dosing regimen. resting HR was significantly and dose-dependently lowered after dronedarone and to a lesser extent after amiodarone.

ExcerptRelevanceReference
" Resting values of LVEF, FS, +LVdP/dt, and MBP remained unchanged whatever the drug and the dosing regimen, whereas resting HR was significantly and dose-dependently lowered after dronedarone and to a lesser extent after amiodarone."( Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.
Djandjighian, L; Finance, O; Gautier, P; Nisato, D; Pastor, G; Planchenault, J, 2000
)
0.76
" The phase II Dronedarone Atrial FibrillatioN study after Electrical cardioversion (DAFNE) study established 400 mg twice-daily dosing (bid) as the standard dose for dronedarone in the maintenance of sinus rhythm."( Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
Duray, GZ; Hohnloser, SH; Schmitt, J, 2010
)
2.16
" The dosage was reduced to 1 mg/day; there was no need for further adjustment."( Significant sirolimus and dronedarone interaction in a kidney transplant recipient.
Formica, RN; Kulkarni, S; Medwid, AJ; Mills, EA; Tichy, EM,
)
0.43
" Compared with amiodarone, dronedarone has poor bioavailability and a shorter terminal disposition half-life, which dictates a twice-daily dosing regimen."( Dronedarone: an alternative to amiodarone?
Cohenour, FV; Freeman, MK; Hughes, PJ; Price, EM, 2010
)
2.1
" The warfarin dose was decreased to 20 mg/wk, and the INR remained stable with that dosage for the next 11 months."( Elevated international normalized ratio associated with use of dronedarone and warfarin.
Haber, SL; Pogge, EK, 2011
)
0.61
" If a significant interaction is noted, the warfarin dosage should be decreased and the patient should be monitored within 2 weeks to assess the need for further adjustments."( Elevated international normalized ratio associated with use of dronedarone and warfarin.
Haber, SL; Pogge, EK, 2011
)
0.61
" No dosage adjustments are required for patients with renal impairment."( Managing atrial fibrillation in the elderly: critical appraisal of dronedarone.
Fischer, GW; Trigo, P, 2012
)
0.62
"A simple, sensitive and reproducible method was developed on ultra-performance liquid chromatography coupled with photodiode array detection for the quantitative determination of dronedarone hydrochloride (DRO) in drug substance and pharmaceutical dosage forms."( Stability-indicating UPLC method for determining related substances and degradants in dronedarone.
Cholleti, VK; Pydimarry, SP; Vangala, RR, 2014
)
0.82
" The increased plasma concentrations after oral dosing to hyperlipidemic rats appears to be attributable to a direct effect on metabolizing enzymes or transport proteins."( The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats.
Brocks, DR; Jardan, YA, 2016
)
0.74
" Overall, the obtained data confirmed that the inclusion complexes prepared by kneading followed by spray-drying, especially those based on HP-β-CD, appeared to be the most promising formulations and, therefore, could be encouragingly explored in the development of novel pharmaceutical dosage forms containing DRO, presumably with reduced side effects and improved safety profile."( Comparative evaluation of the hepatotoxicity, phototoxicity and photosensitizing potential of dronedarone hydrochloride and its cyclodextrin-based inclusion complexes.
Macedo, LB; Marcolino, AIP; Mitjans, M; Nogueira-Librelotto, DR; Rolim, CMB; Vinardell, MP, 2019
)
0.73
"The production of 3D-printed dosage forms requires the preparation of high-quality filaments containing an active pharmaceutical ingredient (API)."( Preparation of Filaments and the 3D Printing of Dronedarone HCl Tablets for Treating Cardiac Arrhythmias.
Gretić, M; Kezerić, K; Matijašić, G; Petanjek, J; Vukelić, E, 2019
)
0.77
" Reduced apixaban and rivaroxaban dosing regimens are recommended when dronedarone is co-administered to patients with AF."( Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
He, QF; Jiao, Z; Wen, HN; Xiang, XQ; Yu, JG, 2022
)
1.15
" Model verification was performed for intravenous and oral (single and multiple) dosing regimens."( Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Ang, XJ; Chan, ECY; Leow, JWH, 2023
)
1.14
"Dronedarone and NDBD PK following clinically relevant doses of 400 mg dronedarone across single and multiple oral dosing were accurately simulated by incorporating effect of auto-inactivation on dose nonlinearities."( Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Ang, XJ; Chan, ECY; Leow, JWH, 2023
)
2.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
1-benzofuransA member of the class of benzofurans consisting of a 1-benzofuran skeleton and its substituted derivatives thereof.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (53)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency21.40030.002541.796015,848.9004AID1347395; AID1347397; AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency16.97973.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency21.27180.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency17.65890.173734.304761.8120AID1346859; AID1346924
Fumarate hydrataseHomo sapiens (human)Potency23.62590.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency23.36170.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency17.65890.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency5.34440.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency2.63330.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency30.05780.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency18.83360.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency33.71360.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency33.49150.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency29.37160.000417.946075.1148AID1346784; AID1346795; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.45040.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency20.49330.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency25.85980.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency21.10440.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency15.41720.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.64090.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency4.21630.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.21060.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743078
GVesicular stomatitis virusPotency12.14480.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency3.06630.00108.379861.1304AID1645840
polyproteinZika virusPotency23.62590.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency25.85600.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency22.08550.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency26.83250.023723.228263.5986AID743223
caspase-3Homo sapiens (human)Potency18.83360.013326.981070.7614AID1346978
aryl hydrocarbon receptorHomo sapiens (human)Potency36.52700.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.84930.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency29.84930.001628.015177.1139AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency26.83250.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency22.614219.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency19.50170.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency12.35700.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency12.11560.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency29.84700.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.48890.000627.21521,122.0200AID743202
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency29.84930.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency18.20780.00339.158239.8107AID1347407; AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency12.14480.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency30.04740.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency29.84930.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency22.38720.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency12.14480.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency33.49150.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency33.49150.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency12.14480.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)3.92000.00022.45859.9600AID1804171
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)1.65810.00091.901410.0000AID240820; AID576612
NACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)IC50 (µMol)6.84000.00041.441910.0000AID1754614
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (205)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (73)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (45)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytosolNACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1617350Inhibition of recombinant human CYP2J2 expressed in baculovirus infected insect cells co-expressing NADPH-CYP reductase and cytochrome b5 assessed as reduction in CYP2J2-mediated EPA epoxidation by measuring sum of EEQ and DiHETEs level at 1 to 50 uM usin2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID1754614Inhibition of NLRP3 inflammasome in LPS-primed mouse J774.A1 cells assessed as reduction in IL-1beta secretion preincubated with compound for 1 hr followed by nigericin stimulation for 1 hr by ELISA2021Bioorganic & medicinal chemistry letters, 08-15, Volume: 46Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity.
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1480298Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1346684Human Kv1.5 (Voltage-gated potassium channels)2014European journal of medicinal chemistry, Jun-23, Volume: 81Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (486)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (1.44)18.2507
2000's93 (19.14)29.6817
2010's318 (65.43)24.3611
2020's68 (13.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.94 (24.57)
Research Supply Index6.31 (2.92)
Research Growth Index5.67 (4.65)
Search Engine Demand Index151.96 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (85.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials40 (7.89%)5.53%
Reviews116 (22.88%)6.00%
Case Studies36 (7.10%)4.05%
Observational5 (0.99%)0.25%
Other310 (61.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double Blind, Randomized, Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Dronedarone (SR33589B) at 300, 400, or 600 mg BID for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation [NCT01213368]Phase 2181 participants (Actual)Interventional2010-09-30Completed
Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus [NCT01266681]100 participants (Anticipated)Interventional2011-03-31Not yet recruiting
A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL) [NCT00174785]Phase 34,628 participants (Actual)Interventional2005-06-30Completed
Effect of Prolonged Use of Dronedarone on Recurrence in Patients With Non-paroxysmal Atrial Fibrillation After Radiofrequency Ablation [NCT05655468]Phase 4268 participants (Anticipated)Interventional2023-03-29Recruiting
Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation - a Randomized Multicentre Study Comparing Atrial Fibrillation Ablation Strategy With Optimized Conventional Pharmacological Strategy After 12 Months Follow-up. [NCT02294955]152 participants (Actual)Interventional2008-05-31Active, not recruiting
Using Cryoballoon Ablation as Initial Treatment for Patients With Persistent Atrial Fibrillation Comparing to Anti-arrhythmic Drugs [NCT04942834]286 participants (Anticipated)Interventional2021-08-31Not yet recruiting
A Randomized, International, Multi-center, Open-label Study to Document Optimal Timing of Initiation of Dronedarone Treatment After Conversion With Loading Dose of Amiodarone in Patients With Persistent Atrial Fibrillation Requiring Conversion of AF. [NCT01140581]Phase 4402 participants (Actual)Interventional2010-09-30Completed
Preoperative Colchicine, Dronedarone Or Amiodarone for Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG; A Comparative Study [NCT03905759]Phase 2/Phase 348 participants (Anticipated)Interventional2019-04-03Recruiting
A Randomized, International, Multi-center, Open-label Study to Document Pharmacokinetics and Optimal Timing of Initiation of Dronedarone Treatment Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation Whatever the Re [NCT01199081]Phase 4154 participants (Actual)Interventional2010-10-31Completed
A Phase IV, Double-blind, Placebo-controlled, Canadian Multicentre Study Comparing Two Treatment Strategies of Dronedarone Administration Following ELECTive caRdioversion for Prevention of Symptomatic Atrial Fibrillation (AF) Recurrence [NCT01026090]Phase 4292 participants (Actual)Interventional2009-11-30Terminated(stopped due to 'Sponsor decision following recruitment issues, not related to any safety concerns in the study)
Antiarrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease [NCT00696631]Phase 3653 participants (Actual)Interventional2002-06-30Terminated(stopped due to Terminated as the active treatment was associated with an increased hazard)
Randomized Double Blind Trial to Evaluate the Efficacy and Safety of Dronedarone (400mg BID) Versus Amiodarone (600mg Daily for 28 Days, Then 200mg Daily Thereafter) for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrill [NCT00489736]Phase 3504 participants (Actual)Interventional2007-06-30Completed
Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation [NCT01070667]Phase 450 participants (Anticipated)Interventional2010-03-31Not yet recruiting
The Effect of the Addition of Dronedarone to, Versus Increase of, Existing Conventional Rate Control Medication on Ventricular Rate During Persistent Atrial Fibrillation [NCT01047566]Phase 4183 participants (Actual)Interventional2010-04-30Completed
Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion [NCT01991119]98 participants (Actual)Interventional2011-05-31Completed
First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication [NCT05939076]Phase 3220 participants (Anticipated)Interventional2023-08-21Not yet recruiting
A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors [NCT01151137]Phase 33,236 participants (Actual)Interventional2010-07-31Terminated(stopped due to The study was stopped because of safety concerns)
A Placebo-Controlled, Double-Blind, Randomized, Multi-center Study to Assess the Effects of Dronedarone 400 mg BID on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement [NCT01198873]Phase 476 participants (Actual)Interventional2010-09-30Terminated
Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) [NCT00697086]Phase 3174 participants (Actual)Interventional2002-08-31Completed
SLR/NMA of Multaq® vs Sotalol to Assess for Safety in Patients With Atrial Fibrillation (AFib) [NCT05279833]87,810 participants (Actual)Observational2021-09-24Completed
Dronedarone for Patients With Recurrent ICD Shocks Due to Ventricular Arrhythmia Resistant to Their Antiarrhythmic Drug Therapy or Ablation [NCT01430806]20 participants (Anticipated)Interventional2011-10-31Not yet recruiting
Relative Bioavailability of a Single Dose of 150 mg Dabigatran Etexilate (Capsule) When Administered Alone or in Combination With a Single Dose of 400 mg Dronedarone Tablet) or in Combination With 400 mg Bid Dronedarone (Tablet) at Steady State in Healthy [NCT01306162]Phase 136 participants (Actual)Interventional2011-02-28Completed
A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Assess the Effects of Dronedarone 400 mg BID for 12 Weeks on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers [NCT01135017]Phase 4112 participants (Actual)Interventional2010-07-31Terminated
Early Aggressive Invasive Intervention for Atrial Fibrillation [NCT02825979]303 participants (Actual)Interventional2017-01-31Active, not recruiting
EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS) [NCT00259428]Phase 3615 participants (Actual)Interventional2001-11-30Completed
American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS) [NCT00259376]Phase 3629 participants (Actual)Interventional2001-11-30Completed
Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence Post Ablation: The EDORA Trial [NCT04704050]Phase 422 participants (Actual)Interventional2021-05-15Terminated(stopped due to Sponsor withdrew funding)
SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI [NCT01182376]Phase 333 participants (Actual)Interventional2010-11-30Completed
A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation [NCT01522651]Phase 2134 participants (Actual)Interventional2012-01-24Completed
Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation [NCT05130268]Phase 43,000 participants (Anticipated)Interventional2021-10-29Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00174785 (5) [back to overview]Adjudicated Cardiovascular Death
NCT00174785 (5) [back to overview]Cardiovascular Death
NCT00174785 (5) [back to overview]Death From Any Cause
NCT00174785 (5) [back to overview]First Hospitalization for Cardiovascular Reason
NCT00174785 (5) [back to overview]First Hospitalization for Cardiovascular Reason or Death From Any Cause
NCT00489736 (3) [back to overview]Occurrence of the Main Safety Endpoint (MSE) Defined as Thyroid, Hepatic, Pulmonary, Neurological, Skin, Eye, or Gastrointestinal Specific Treatment Emergent Events or Premature Study Drug Discontinuation Following Any Adverse Event
NCT00489736 (3) [back to overview]Occurrence of the MSE Excluding Gastrointestinal Specific Treatment Emergent Events Defined as Diarrhoea, Nausea, Vomiting
NCT00489736 (3) [back to overview]Treatment Failure
NCT01135017 (6) [back to overview]Incidence Rate of Electrical Cardioversion (or Overdrive Pacing)
NCT01135017 (6) [back to overview]AF Burden During the First 4 Weeks of Treatment and After 4-week Treatment
NCT01135017 (6) [back to overview]Atrial Fibrillation (AF) Burden During the 12-week Treatment Period
NCT01135017 (6) [back to overview]Atrial Fibrillation Severity Scale (AFSS) Scores
NCT01135017 (6) [back to overview]Average Ventricular Rate During AF Episodes
NCT01135017 (6) [back to overview]Overview of Adverse Events (AE)
NCT01151137 (7) [back to overview]Deaths
NCT01151137 (7) [back to overview]Overview of Adverse Events [AE]
NCT01151137 (7) [back to overview]Overview of Cardiovascular Events
NCT01151137 (7) [back to overview]Overview of the Two Co-primary Outcomes
NCT01151137 (7) [back to overview]Time to Cardiovascular Death (Cumulative Incidence Function)
NCT01151137 (7) [back to overview]Time to First Co-primary Outcome (Cumulative Incidence Function)
NCT01151137 (7) [back to overview]Time to Second Co-primary Outcome (Cumulative Incidence Function)
NCT01182376 (1) [back to overview]LA Fibrosis
NCT01198873 (5) [back to overview]Change From Baseline in Left Atrial Volume Index (LAVi)
NCT01198873 (5) [back to overview]Changes From Baseline in Left Atrial Function
NCT01198873 (5) [back to overview]Changes From Baseline in Left Ventricular Function
NCT01198873 (5) [back to overview]Changes From Baseline in Left Atrial Dimension
NCT01198873 (5) [back to overview]Changes From Baseline in Left Ventricular Ejection Fraction (LVEF)
NCT01306162 (4) [back to overview]Total Dabigatran: Maximum Measured Concentration (Cmax)
NCT01306162 (4) [back to overview]Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01306162 (4) [back to overview]Free Dabigatran: Maximum Measured Concentration (Cmax)
NCT01306162 (4) [back to overview]Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01522651 (4) [back to overview]Atrial Fibrillation Burden (AFB) at Baseline
NCT01522651 (4) [back to overview]Percent Change From Baseline in Atrial Fibrillation Burden (AFB) by Week 12
NCT01522651 (4) [back to overview]Absolute Change From Baseline in AFB by Week 12
NCT01522651 (4) [back to overview]Percentage of Participants Who Had ≥ 30%, ≥ 50%, or ≥ 70% Reduction From Baseline in AFB

Adjudicated Cardiovascular Death

The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years

Interventionparticipants (Number)
Dronedarone 400mg Bid63
Placebo90

[back to top]

Cardiovascular Death

The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years

Interventionparticipants (Number)
Dronedarone 400mg Bid65
Placebo94

[back to top]

Death From Any Cause

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years

Interventionparticipants (Number)
Dronedarone 400mg Bid116
Placebo139

[back to top]

First Hospitalization for Cardiovascular Reason

The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years

Interventionparticipants (Number)
Dronedarone 400mg Bid675
Placebo859

[back to top]

First Hospitalization for Cardiovascular Reason or Death From Any Cause

The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years

Interventionparticipants (Number)
Dronedarone 400mg Bid734
Placebo917

[back to top]

Occurrence of the Main Safety Endpoint (MSE) Defined as Thyroid, Hepatic, Pulmonary, Neurological, Skin, Eye, or Gastrointestinal Specific Treatment Emergent Events or Premature Study Drug Discontinuation Following Any Adverse Event

"The considered event is the occurrence of the MSE defined as thyroid, hepatic, pulmonary, neurological, skin, eye, or gastrointestinal specific treatment emergent events or premature study drug discontinuation following any adverse event (AE), whichever comes first. The analysis is performed on the time from first study drug intake to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months

Interventionparticipants (Number)
Dronedarone 400mg Bid83
Amiodarone 600mg/200mg od107

[back to top]

Occurrence of the MSE Excluding Gastrointestinal Specific Treatment Emergent Events Defined as Diarrhoea, Nausea, Vomiting

"The considered event is the occurrence of the MSE excluding gastrointestinal specific treatment emergent events defined as diarrhoea, nausea, vomiting. The analysis is performed on the time from first study drug intake to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months

Interventionparticipants (Number)
Dronedarone 400mg Bid61
Amiodarone 600mg/200mg od99

[back to top]

Treatment Failure

"The primary event is the treatment failure defined as the first recurrence of atrial fibrillation or premature study drug discontinuation for intolerance or lack of efficacy according to the investigator judgement. The primary efficacy analysis is performed on the time from first study drug intake to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months

Interventionparticipants (Number)
Dronedarone 400mg Bid184
Amiodarone 600mg/200mg od141

[back to top]

Incidence Rate of Electrical Cardioversion (or Overdrive Pacing)

"Electrical cardioversion is a procedure in which an electric shock is used to restore normal heart rhythm. Overdrive pacing is a procedure in which an artificial cardiac pacemaker is used to increase the heart rate in order to suppress certain arrhythmias.~Incidence rate of electrical cardioversion (or overdrive pacing) is expressed as the number of participants that was cardioverted or paced during the study." (NCT01135017)
Timeframe: 12 weeks

Interventionparticipants (Number)
Placebo1
Dronedarone0

[back to top]

AF Burden During the First 4 Weeks of Treatment and After 4-week Treatment

AF burden at each pacemaker interrogation as evaluated centrally by the Pacemaker Core Lab (NCT01135017)
Timeframe: 4 weeks and 12 weeks after randomization

,
Interventionpercent time in AF (Geometric Mean)
Week 1 - 4 (n =54, 49)Week 5 - 12 (n =54, 54)
Dronedarone3.624.28
Placebo8.999.37

[back to top]

Atrial Fibrillation (AF) Burden During the 12-week Treatment Period

"AF burden, defined as the percent time a subject is in AF, was evaluated centrally by a Pacemaker Core Lab based on pacemaker interrogation reports including Electrogram (EGM) data provided by the Investigator.~AF burden during the 12-week treatment period was defined as the duration-weighted average of AF burden collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing." (NCT01135017)
Timeframe: Baseline (before randomization), 4 weeks and 12 weeks after randomization

,
Interventionpercent time in AF (Geometric Mean)
Baseline12-week treatment period
Dronedarone10.144.63
Placebo8.779.90

[back to top]

Atrial Fibrillation Severity Scale (AFSS) Scores

"The University of Toronto Atrial Fibrillation Severity Scale is an instrument to assess the subject-perceived AF burden and AF symptom severity. It consists in a questionnaire plus a scoring algorithm.~AF Burden score ranges from 3 to 30 and higher scores indicate greater AF burden.~AF symptoms severity score ranges from 0 to 35 and higher scores indicate extremely severe AF symptoms." (NCT01135017)
Timeframe: Baseline (before randomization) and 12 weeks after randomization

,
Interventionunits on a scale (Mean)
AF burden at baseline (n =45, 34)AF burden after 12-week treatment (n =38, 31)AF symptoms at baseline (n =55, 55)AF symptoms after 12-week treatment (n =54, 53)
Dronedarone12.7612.488.367.42
Placebo13.7213.308.478.06

[back to top]

Average Ventricular Rate During AF Episodes

"Ventricular rates of AF episodes were obtained from pacemaker interrogation and EGM review.~The average ventricular rate during AF episodes in the 12-week treatment period was defined as the duration-weighted average of the ventricular rates collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing." (NCT01135017)
Timeframe: Baseline (before randomization), 4 weeks and 12 weeks after randomization

,
Interventionbeats/min (Mean)
Baseline (n =49, 47)Week 1-12 (n =49, 48)--- Week 1-4 (n =44, 41)--- Week 5-12 (n =47, 42)
Dronedarone90.6891.2891.9388.56
Placebo93.0295.6796.8095.58

[back to top]

Overview of Adverse Events (AE)

AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study. (NCT01135017)
Timeframe: from first study drug intake up to 10 days after the last study drug intake

,
Interventionparticipants (Number)
Any AE- Any serious AE- Any AE leading to death- Any AE leading to treatment discontinuation
Dronedarone37708
Placebo31703

[back to top]

Deaths

Deaths were classified according to the primary cause of death. (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

,
Interventionparticipants (Number)
Any death- Cardiovascular death--- Cardiac arrhythmic death
Dronedarone252113
Placebo13104

[back to top]

Overview of Adverse Events [AE]

AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study. (NCT01151137)
Timeframe: from first study drug intake up to 10 days after the last study drug intake

,
Interventionparticipants (Number)
Any AE- Any serious AE- Any AE leading to death- Any AE leading to treatment discontinuation- Any AE leading to hospitalization
Dronedarone797113421295
Placebo6007708071

[back to top]

Overview of Cardiovascular Events

(NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

,
Interventionparticipants (Number)
MI or unstable angina pectoris- MIStroke- Ischemic strokeSystemic arterial embolismEpisode of heart failure- Hospitalization due to heart failureUnplanned hospitalization for cardiovascular cause
Dronedarone1532318111543113
Placebo821090552459

[back to top]

Overview of the Two Co-primary Outcomes

"First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions [MI], or cardiovascular death.~Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause.~Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks [TIA], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

,
Interventionparticipants (Number)
First co-primary endpointSecond co-primary endpoint
Dronedarone43127
Placebo1967

[back to top]

Time to Cardiovascular Death (Cumulative Incidence Function)

"Time to cardiovascular death was defined as the time from randomization to the death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

,
Interventionproportion of participants (Number)
Cumulative incidence at 14 daysCumulative incidence at 30 daysCumulative incidence at 90 daysCumulative incidence at 180 daysCumulative incidence at 270 daysCumulative incidence at 360 days
Dronedarone0.0030.0050.0080.0220.0260.026
Placebo0.0010.0030.0040.0040.0270.027

[back to top]

Time to First Co-primary Outcome (Cumulative Incidence Function)

"Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

,
Interventionproportion of participants (Number)
Cumulative incidence at 14 daysCumulative incidence at 30 daysCumulative incidence at 90 daysCumulative incidence at 180 daysCumulative incidence at 270 daysCumulative incidence at 360 days
Dronedarone0.0090.0130.0210.0420.0450.045
Placebo0.0020.0030.0070.0130.0380.038

[back to top]

Time to Second Co-primary Outcome (Cumulative Incidence Function)

"Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

,
Interventionproportion of participants (Number)
Cumulative incidence at 14 daysCumulative incidence at 30 daysCumulative incidence at 90 daysCumulative incidence at 180 daysCumulative incidence at 270 daysCumulative incidence at 360 days
Dronedarone0.0200.0340.0690.1100.1370.137
Placebo0.0050.0140.0330.0590.0990.099

[back to top]

LA Fibrosis

The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment. (NCT01182376)
Timeframe: baseline, 1 year

Interventionpercentage of fibrosis (Mean)
Placebo24.6
Multaq® (Dronedarone)16.8

[back to top]

Change From Baseline in Left Atrial Volume Index (LAVi)

"Left Atrial Volume index (LAVi) was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab.~Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis." (NCT01198873)
Timeframe: baseline (before randomization) and post-baseline (after 3-12 months of treatment)

,
Interventionmililiters/m2 (Mean)
Baseline (n =33, 26)Post-baseline (n =32, 26)Change from baseline (n =32, 26)
Dronedarone37.71530.823-6.892
Placebo37.55529.191-8.438

[back to top]

Changes From Baseline in Left Atrial Function

"left atrial (LA) function was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab.~Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis." (NCT01198873)
Timeframe: baseline (before randomization) and post-baseline (after 3-12 months of treatment)

,
Interventionmililiters (Mean)
LA passive emptying volume (n = 19, 19)LA conduit volume (n =29, 25)LA active emptying volume (n = 19, 19)LA passive emptying fraction (n = 19, 19)LA active emptying fraction (n = 19, 19)
Dronedarone-4.566-0.7641.198-0.0190.067
Placebo-10.783-1.366-0.052-0.0740.057

[back to top]

Changes From Baseline in Left Ventricular Function

"left ventricular (LV) function was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab.~Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis." (NCT01198873)
Timeframe: baseline (before randomization) and post-baseline (after 3-12 months of treatment)

,
Interventioncentimeters/second (Mean)
Peak early diastolic transmitral flow velocity (E)Mitral annular velocity (E')Peak late diastolic transmitral flow velocity (A)E/E' ratio
Dronedarone-10.497-0.1194.319-1.443
Placebo5.1650.8470.076-0.787

[back to top]

Changes From Baseline in Left Atrial Dimension

"Maximal left atrial diameter in the anteroposterior dimension was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab.~Participants who discontinued after completing at least 3 months of treatment were assessed after last drug intake and data were included in the analysis." (NCT01198873)
Timeframe: baseline (before randomization) and post-baseline (after 3-12 months of treatment)

Interventioncentimeters (Mean)
Placebo-0.124
Dronedarone-0.166

[back to top]

Changes From Baseline in Left Ventricular Ejection Fraction (LVEF)

"Left Ventricular Ejection Fraction (LVEF) was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab.~Participants who discontinued after completing at least 3 months of treatment were assessed after last drug intake and data were included in the analysis." (NCT01198873)
Timeframe: baseline (before randomization) and post-baseline (after 3-12 months of treatment)

Interventionpercentage of blood pumped out (Mean)
Placebo0.948
Dronedarone1.147

[back to top]

Total Dabigatran: Maximum Measured Concentration (Cmax)

Maximum measured concentration of total dabigatran in plasma, per period. (NCT01306162)
Timeframe: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration

Interventionng/mL (Geometric Mean)
150mg DE (TrtA)149
150mg DE + 400mg DR (TrtB)282
150mg DE + 400mg DR 2h Later (TrtC)166
150mg DE + 400mg DR Bid Same Time (TrtD)288
150mg DE + 400mg DR Bid 2h Later (TrtE)163

[back to top]

Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity. (NCT01306162)
Timeframe: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration

Interventionng*hr/mL (Geometric Mean)
150mg DE (TrtA)919
150mg DE + 400mg DR (TrtB)2110
150mg DE + 400mg DR 2h Later (TrtC)1110
150mg DE + 400mg DR Bid Same Time (TrtD)2100
150mg DE + 400mg DR Bid 2h Later (TrtE)1260

[back to top]

Free Dabigatran: Maximum Measured Concentration (Cmax)

Maximum measured concentration of free dabigatran in plasma, per period. (NCT01306162)
Timeframe: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration

Interventionng/mL (Geometric Mean)
150mg DE (TrtA)126
150mg DE + 400mg DR (TrtB)239
150mg DE + 400mg DR 2h Later (TrtC)133
150mg DE + 400mg DR Bid Same Time (TrtD)241
150mg DE + 400mg DR Bid 2h Later (TrtE)138

[back to top]

Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity. (NCT01306162)
Timeframe: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration

Interventionng*hr/mL (Geometric Mean)
150mg DE (TrtA)1160
150mg DE + 400mg DR (TrtB)2520
150mg DE + 400mg DR 2h Later (TrtC)1440
150mg DE + 400mg DR Bid Same Time (TrtD)2570
150mg DE + 400mg DR Bid 2h Later (TrtE)1510

[back to top]

Atrial Fibrillation Burden (AFB) at Baseline

AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Geometric mean is the mean of log-transformed AFB exponentiated. (NCT01522651)
Timeframe: Baseline

InterventionPercentage of total recording time (Geometric Mean)
Placebo12.7
Ranolazine 750 mg10.8
Dronedarone 225 mg11.6
Ranolazine 750 mg + Dronedarone 225 mg11.7
Ranolazine 750 mg + Dronedarone 150 mg11.7

[back to top]

Percent Change From Baseline in Atrial Fibrillation Burden (AFB) by Week 12

AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment. Geometric mean is the mean of log-transformed AFB exponentiated. (NCT01522651)
Timeframe: Baseline; Week 12

Interventionpercent change (Geometric Mean)
Placebo-5.9
Ranolazine 750 mg-23.0
Dronedarone 225 mg3.5
Ranolazine 750 mg + Dronedarone 225 mg-59.1
Ranolazine 750 mg + Dronedarone 150 mg-45.5

[back to top]

Absolute Change From Baseline in AFB by Week 12

AFB is defined as the total time a participant is in AT/AF expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment. (NCT01522651)
Timeframe: Baseline; Week 12

,,,,
Interventionpercentage of total recording time (Mean)
BaselineAbsolute Change From Baseline in AFB by Week 12
Dronedarone 225 mg19.15.6
Placebo16.84.6
Ranolazine 750 mg17.3-3.1
Ranolazine 750 mg + Dronedarone 150 mg16.7-3.9
Ranolazine 750 mg + Dronedarone 225 mg16.8-4.7

[back to top]

Percentage of Participants Who Had ≥ 30%, ≥ 50%, or ≥ 70% Reduction From Baseline in AFB

AFB was defined as the total time a participant was in AT/AF expressed as a percentage of total recording time. (NCT01522651)
Timeframe: Week 12

,,,,
Interventionpercentage of participants (Number)
≥ 30% Reduction From Baseline AFB≥ 50% Reduction From Baseline AFB≥ 70% Reduction From Baseline AFB
Dronedarone 225 mg21.713.08.7
Placebo22.216.711.1
Ranolazine 750 mg50.022.216.7
Ranolazine 750 mg + Dronedarone 150 mg54.554.527.3
Ranolazine 750 mg + Dronedarone 225 mg45.045.045.0

[back to top]